StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc. (GILD) stock

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 12/30104% above fair value
$168.98−1.28 (-0.75%)

Close on Nov 18, 2026Market cap $209.59BP/E –Yield 1.87%

Gilead Sciences operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Gilead Sciences's operating income for the twelve months ending Sep 30, 2026 was -$2.36B, down 122.5% year over year. For fiscal 2025 it was $10.02B, up 503.0% from the year before. Over ten years it grew -7.6% a year on average. The highest annual figure on record is $22.19B in fiscal 2015.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$10.02B+503.0%
FY2024Dec 31, 2024$1.66B-78.1%
FY2023Dec 31, 2023$7.61B+3.8%
FY2022Dec 31, 2022$7.33B-26.1%
FY2021Dec 31, 2021$9.92B+143.6%
FY2020Dec 31, 2020$4.07B-5.0%
FY2019Dec 31, 2019$4.29B-47.7%
FY2018Dec 31, 2018$8.20B-41.9%
FY2017Dec 31, 2017$14.12B-19.9%
FY2016Dec 31, 2016$17.63B-20.5%
FY2015Dec 31, 2015$22.19B+45.4%
FY2014Dec 31, 2014$15.27B+237.4%
FY2013Dec 31, 2013$4.52B+12.8%
FY2012Dec 31, 2012$4.01B+5.8%
FY2011Dec 31, 2011$3.79B-4.4%
FY2010Dec 31, 2010$3.96B+12.3%
FY2009Dec 31, 2009$3.53B+31.8%
FY2008Dec 31, 2008$2.68B+23.7%
FY2007Dec 31, 2007$2.16B–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$3.46B+4.1%
Q2 FY2026Jun 30, 2026-$10.39B-520.1%
Q1 FY2026Mar 31, 2026$2.59B+15.6%
Q4 FY2025Dec 31, 2025$1.98B-19.1%
Q3 FY2025Sep 30, 2025$3.33B+274.7%
Q2 FY2025Jun 30, 2025$2.47B-6.4%
Q1 FY2025Mar 31, 2025$2.24B–
Q4 FY2024Dec 31, 2024$2.45B+52.1%
Q3 FY2024Sep 30, 2024$888.00M-66.1%
Q2 FY2024Jun 30, 2024$2.64B+58.8%
Q1 FY2024Mar 31, 2024-$4.32B-353.5%
Q4 FY2023Dec 31, 2023$1.61B-28.9%
Q3 FY2023Sep 30, 2023$2.62B-7.5%
Q2 FY2023Jun 30, 2023$1.67B-17.9%
Q1 FY2023Mar 31, 2023$1.71B+765.5%
Q4 FY2022Dec 31, 2022$2.27B+141.2%
Q3 FY2022Sep 30, 2022$2.84B-26.2%
Q2 FY2022Jun 30, 2022$2.03B-9.7%
Q1 FY2022Mar 31, 2022$197.00M-93.2%
Q4 FY2021Dec 31, 2021$940.00M-64.5%
Q3 FY2021Sep 30, 2021$3.84B+92.0%
Q2 FY2021Jun 30, 2021$2.25B–
Q1 FY2021Mar 31, 2021$2.89B+20.3%
Q4 FY2020Dec 31, 2020$2.65B+142.5%
Q3 FY2020Sep 30, 2020$2.00B–
Q2 FY2020Jun 30, 2020-$2.98B-222.8%
Q1 FY2020Mar 31, 2020$2.40B+7.4%
Q4 FY2019Dec 31, 2019$1.09B-4.5%
Q3 FY2019Sep 30, 2019-$1.47B-156.2%
Q2 FY2019Jun 30, 2019$2.43B+6.6%
Q1 FY2019Mar 31, 2019$2.24B+3.9%
Q4 FY2018Dec 31, 2018$1.14B-50.1%
Q3 FY2018Sep 30, 2018$2.62B-31.2%
Q2 FY2018Jun 30, 2018$2.28B-46.4%
Q1 FY2018Mar 31, 2018$2.15B-42.8%
Q4 FY2017Dec 31, 2017$2.29B-43.4%
Q3 FY2017Sep 30, 2017$3.81B–
Q2 FY2017Jun 30, 2017$4.25B–
Q1 FY2017Mar 31, 2017$3.77B–
Q4 FY2016Dec 31, 2016$4.05B–

More Gilead Sciences figures

See a number that looks wrong?